With estrogen-responsive luminal A and Luminal B metastatic tumors, there is often no distinction in the treatment of disease, which often involves an anti-estrogen. However, due to drug resistance, many are prescribed combination therapy.
“The two categories of treatment that really have, now, come into the mainstream and standard of care, [are] mTOR inhibitors and CDK 4/6 inhibitors,” says Angela DeMichele, MD, MSCE, professor of medicine and epidemiology, University of Pennsylvania.
In the past few years there have been several new drug approvals.
These oral therapies are well tolerated, with less intense side effects than chemotherapy. However, since these drugs are taken at the patient’s discretion, it is important to ensure adherence.